Literature DB >> 14561676

Acute adenosinergic cardioprotection in ischemic-reperfused hearts.

John P Headrick1, Ben Hack, Kevin J Ashton.   

Abstract

Cells of the cardiovascular system generate and release purine nucleoside adenosine in increasing quantities when constituent cells are "stressed" or subjected to injurious stimuli. This increased adenosine can interact with surface receptors in myocardial, vascular, fibroblast, and inflammatory cells to modulate cellular function and phenotype. Additionally, adenosine is rapidly reincorporated back into 5'-AMP to maintain the adenine nucleotide pool. Via these receptor-dependent and independent (metabolic) paths, adenosine can substantially modify the acute response to ischemic insult, in addition to generating a more sustained ischemia-tolerant phenotype (preconditioning). However, the molecular basis for acute adenosinergic cardioprotection remains incompletely understood and may well differ from more widely studied preconditioning. Here we review current knowledge and some controversies regarding acute cardioprotection via adenosine and adenosine receptor activation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14561676     DOI: 10.1152/ajpheart.00407.2003

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  40 in total

Review 1.  Perspectives of purinergic signaling in stem cell differentiation and tissue regeneration.

Authors:  Talita Glaser; Angélica Regina Cappellari; Micheli Mainardi Pillat; Isabele Cristiana Iser; Márcia Rosângela Wink; Ana Maria Oliveira Battastini; Henning Ulrich
Journal:  Purinergic Signal       Date:  2011-12-06       Impact factor: 3.765

Review 2.  The gap junction cellular internet: connexin hemichannels enter the signalling limelight.

Authors:  W Howard Evans; Elke De Vuyst; Luc Leybaert
Journal:  Biochem J       Date:  2006-07-01       Impact factor: 3.857

3.  Pretreatment with adenosine and adenosine A1 receptor agonist protects against intestinal ischemia-reperfusion injury in rat.

Authors:  V Haktan Ozacmak; Hale Sayan
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

4.  Cardiac-restricted overexpression of the A(2A)-adenosine receptor in FVB mice transiently increases contractile performance and rescues the heart failure phenotype in mice overexpressing the A(1)-adenosine receptor.

Authors:  Tung O Chan; Hajime Funakoshi; Jianliang Song; Xue-Qian Zhang; JuFang Wang; Paul H Chung; Brent R DeGeorge; Xue Li; Jin Zhang; David E Herrmann; Maura Diamond; Eman Hamad; Steven R Houser; Walter J Koch; Joseph Y Cheung; Arthur M Feldman
Journal:  Clin Transl Sci       Date:  2008-09       Impact factor: 4.689

Review 5.  Adenosine receptors and reperfusion injury of the heart.

Authors:  John P Headrick; Robert D Lasley
Journal:  Handb Exp Pharmacol       Date:  2009

6.  Methotrexate modulates the kinetics of adenosine in humans in vivo.

Authors:  N P Riksen; P Barrera; P H H van den Broek; P L C M van Riel; P Smits; G A Rongen
Journal:  Ann Rheum Dis       Date:  2005-11-24       Impact factor: 19.103

7.  Contractile effects of adenosine, coronary flow and perfusion pressure in murine myocardium.

Authors:  Laura Willems; John P Headrick
Journal:  Pflugers Arch       Date:  2006-10-28       Impact factor: 3.657

Review 8.  The role of purinergic signaling in the liver and in transplantation: effects of extracellular nucleotides on hepatic graft vascular injury, rejection and metabolism.

Authors:  Guido Beldi; Keiichi Enjyoji; Yan Wu; Lindsay Miller; Yara Banz; Xiaofeng Sun; Simon C Robson
Journal:  Front Biosci       Date:  2008-01-01

Review 9.  G-Protein-Coupled Receptors in Heart Disease.

Authors:  Jialu Wang; Clarice Gareri; Howard A Rockman
Journal:  Circ Res       Date:  2018-08-31       Impact factor: 17.367

10.  Apyrase treatment of myocardial infarction according to a clinically applicable protocol fails to reduce myocardial injury in a porcine model.

Authors:  Jesper van der Pals; Sasha Koul; Michael I Götberg; Göran K Olivecrona; Martin Ugander; Mikael Kanski; Andreas Otto; Matthias Götberg; Håkan Arheden; David Erlinge
Journal:  BMC Cardiovasc Disord       Date:  2010-01-04       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.